Opinion
In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.
Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.
In the wake of the FDA’s rejection of Lykos Therapeutics’ proposal for MDMA-Assisted therapy for PTSD, a therapist advocates for wider access to ketamine-assisted psychotherapy.
A trauma survivor’s experience with ketamine may offer new avenues for understanding the complex relationship between physical pain and mental health.
The death of Matthew Perry shows that the standard of care for clinical practice with ketamine should not include reintroducing those with a prior history of dependence and addiction to resumption of ketamine use.
As research on psychedelics faces a stifling regulatory environment, limited funding and methodological challenges, we need foundations and other entities to accelerate high-quality science and policy evolution to advance our understanding of psychedelic substances and the potential for scalable therapeutics.
Howard Kornfeld, MD, a Distinguished Fellow of the American Society of Addiction Medicine (ASAM), and an addiction medicine and pain specialist practicing for over thirty years, addresses concerns about MDMA-assisted therapy ahead of the FDA decision.
Conversations about the pending FDA decision on MDMA-assisted therapy has brought to light misconceptions about training and standards for therapists involved in psychedelic therapies.
As MDMA/s potential FDA rescheduling approaches, there has been a sudden hullabaloo of negativity, false claims of risks, and undeserved criticism of the studies by MAPS, MAPS PBC, and Lykos Therapeutics.
